Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

NEW YORK--()--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces participation at the following upcoming conferences:

  • Citi’s 14ᵗʰ Annual Biotech Conference
    • Wednesday, September 4, 2019
  • Baird’s 2019 Global Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, September 5, 2019, at 12:15 p.m. Eastern Time.
  • Morgan Stanley’s 17th Annual Global Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Wednesday, September 11, 2019, at 11:40 a.m. Eastern Time
  • Oppenheimer’s Fall Summit Focused on Specialty Pharma and Rare Disease Companies
    • Monday, September 23, 2019
  • Ladenburg Thalmann’s 2019 Healthcare Conference
    • Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, September 24, 2019, at 12:00 p.m. Eastern Time

A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's first two clinical programs using LVV-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, and Leukocyte Adhesion Deficiency-I (LAD-I), a serve pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal. Rocket’s first clinical program using AAV-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket’s pre-clinical pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). For more information about Rocket, please visit www.rocketpharma.com.

Contacts

Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
www.rocketpharma.com
investors@rocketpharma.com

Contacts

Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
www.rocketpharma.com
investors@rocketpharma.com